{
    "clinical_study": {
        "@rank": "31742", 
        "arm_group": [
            {
                "arm_group_label": "Parkinson's Disease", 
                "description": "1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years."
            }, 
            {
                "arm_group_label": "Sunitinib", 
                "description": "Neurologically normal patients, without history of PD, currently undergoing sunitinib treatment for cancer."
            }, 
            {
                "arm_group_label": "Healthy Control", 
                "description": "Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives"
            }
        ], 
        "biospec_descr": {
            "textblock": "Whole blood samples and urine"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This proposal seeks to 1) determine whether there are biomarkers associated with Parkinson's\n      disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients\n      versus controls, and 2) to determine if LRRK2 expression and/or phosphorylation are\n      significantly lowered in the exosomes of individuals treated with the potent LRRK2 kinase\n      inhibitor sunitinib (a multi-kinase inhibitor compound), to establish an assay for on-target\n      effects for future LRRK2 inhibitor clinical trials."
        }, 
        "brief_title": "LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Parkinson's disease inclusion criteria:\n\n        Inclusion criteria will be based on UK Brain Bank criteria for the clinical diagnosis of\n        PD. These require 1) the presence of bradykinesia and either rest tremor or rigidity; 2)\n        asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.\n\n        Sunitinib cohort criteria:\n\n        Neurologically normal patients, without history of PD, currently undergoing sunitinib\n        treatment for cancer. Urine will be collected 4-hours (peak serum drug levels in most\n        people) after their usual AM dosage of drug (cancers include pheochromocytoma, carcinoid,\n        or renal cancer with still normal kidney function (GFR >60), all seen at the UAB\n        Comprehensive Cancer center). Current age from 21 to 99 will be collected.\n\n        Control inclusion criteria: ages of between 21-99 years, a lack of PD in first-degree\n        blood relatives, and a lack of positive responses on more than 3 items on the PD Screening\n        Questionnaire.\n\n        Exclusion Criteria:\n\n        For all subjects:\n\n        include atypical features indicative of a Parkinson-Plus disorder (Progressive\n        Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD))\n        including cerebellar signs, supranuclear gaze palsy, apraxia and other cortical signs, or\n        prominent autonomic failure, neuroleptic treatment at time of onset of parkinsonism,\n        active treatment with a neuroleptic at time of study entry, History of repeated strokes\n        with stepwise progression of parkinsonism, history of repeated head injury, history of\n        definite encephalitis, prominent gait imbalance early in the course (< 5 years), dementia,\n        known severe anemia (hematocrit <30), history of kidney disease and/or current or past\n        glomerular filtration rate (GFR) <60 possibly indicative of kidney disease, or a serious\n        comorbidity that may interfere with participation in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Neurology clinic"
            }
        }, 
        "enrollment": {
            "#text": "700", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860118", 
            "org_study_id": "1U18NS082132"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "abwest@uab.edu", 
                "last_name": "Andrew West, PhD", 
                "phone": "205-996-7697"
            }, 
            "contact_backup": {
                "email": "rclarkrn@uab.edu", 
                "last_name": "Rachel Clark, RN", 
                "phone": "205-996-2647"
            }, 
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35294"
                }, 
                "name": "University of Alabama at Birmingham Sparks Center"
            }, 
            "investigator": {
                "last_name": "Andrew West, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease", 
        "overall_contact": {
            "email": "abwest@uab.edu", 
            "last_name": "Andrew West, PhD", 
            "phone": "205-996-7697"
        }, 
        "overall_contact_backup": {
            "email": "rclarkrn@uab.edu", 
            "last_name": "Rachel Clark, RN", 
            "phone": "205-996-2647"
        }, 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Andrew West, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls.", 
            "measure": "Biomarkers", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860118"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Alabama at Birmingham", 
            "investigator_full_name": "Andrew B. West", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Determine if LRRK2 expression and/or phosphorylation are significantly lowered in the exosomes of individuals treated with the potent LRRK2 kinase inhibitor sunitinib (a multi-kinase inhibitor compound), to establish an assay for on-target effects for future LRRK2 inhibitor clinical trials.", 
            "measure": "LRRK2 expression and/or phosphorylation", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}